128 related articles for article (PubMed ID: 34162561)
1. Clinical Application of Confidence Interval for Monitoring Changes in Tumor Markers to Determine the Responsiveness to Cancer Treatment.
Cho J; Seo DM; Uh Y
Ann Clin Lab Sci; 2021 May; 51(3):321-328. PubMed ID: 34162561
[TBL] [Abstract][Full Text] [Related]
2. Clinical Application of Overlapping Confidence Intervals for Monitoring Changes in Serial Clinical Chemistry Test Results.
Cho J; Seo DM; Uh Y
Ann Lab Med; 2020 May; 40(3):201-208. PubMed ID: 31858759
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP.
Choi JY; Jung SW; Kim HY; Kim M; Kim Y; Kim DG; Oh EJ
World J Gastroenterol; 2013 Jan; 19(3):339-46. PubMed ID: 23372355
[TBL] [Abstract][Full Text] [Related]
4. Monitoring ovarian cancer patients during chemotherapy and follow-up with the serum tumor marker CA125.
Abu Hassaan SO
Dan Med J; 2018 Apr; 65(4):. PubMed ID: 29619933
[TBL] [Abstract][Full Text] [Related]
5. Modeling the time-related fluctuations of AFP and PIVKA-II serum levels in patients with cirrhosis undergoing surveillance for hepatocellular carcinoma.
Ricco G; Cosma C; Bedogni G; Biasiolo A; Guarino M; Pontisso P; Morisco F; Oliveri F; Cavallone D; Bonino F; Plebani M; Brunetto MR
Cancer Biomark; 2020; 29(2):189-196. PubMed ID: 32623383
[TBL] [Abstract][Full Text] [Related]
6. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients.
Lim TS; Kim DY; Han KH; Kim HS; Shin SH; Jung KS; Kim BK; Kim SU; Park JY; Ahn SH
Scand J Gastroenterol; 2016 Mar; 51(3):344-53. PubMed ID: 26340708
[TBL] [Abstract][Full Text] [Related]
7. The clinical association of programmed cell death protein 4 (PDCD4) with solid tumors and its prognostic significance: a meta-analysis.
Li JZ; Gao W; Ho WK; Lei WB; Wei WI; Chan JY; Wong TS
Chin J Cancer; 2016 Nov; 35(1):95. PubMed ID: 27852288
[TBL] [Abstract][Full Text] [Related]
8. Protein induced by vitamin K absence or antagonist-II (PIVKA-II) specifically increased in Italian hepatocellular carcinoma patients.
Viggiani V; Palombi S; Gennarini G; D'Ettorre G; De Vito C; Angeloni A; Frati L; Anastasi E
Scand J Gastroenterol; 2016 Oct; 51(10):1257-62. PubMed ID: 27227515
[TBL] [Abstract][Full Text] [Related]
9. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma.
Feng H; Li B; Li Z; Wei Q; Ren L
BMC Cancer; 2021 Apr; 21(1):401. PubMed ID: 33849479
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of PIVKA-II in hepatocellular carcinoma patients receiving curative ablation: A systematic review and meta-analysis.
Zhang D; Liu Z; Yin X; Qi X; Lu B; Liu Y; Hou J
Int J Biol Markers; 2018 Aug; 33(3):266-274. PubMed ID: 29658364
[TBL] [Abstract][Full Text] [Related]
11. A multicenter study on PIVKA reference interval of healthy population and establishment of PIVKA cutoff value for hepatocellular carcinoma diagnosis in China.
Qin X; Tang G; Gao R; Guo Z; Liu Z; Yu S; Chen M; Tao Z; Li S; Liu M; Wang L; Hou L; Xia L; Cheng X; Han J; Qiu L
Int J Lab Hematol; 2017 Aug; 39(4):392-401. PubMed ID: 28318145
[TBL] [Abstract][Full Text] [Related]
12. Practical delta check limits for tumour markers in different clinical settings.
Yu S; Shin KH; Shin S; Lee H; Yoo SJ; Jun KR; Shin H; Kim S
Clin Chem Lab Med; 2023 Sep; 61(10):1829-1840. PubMed ID: 36994761
[TBL] [Abstract][Full Text] [Related]
13. PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection.
Kim DY; Paik YH; Ahn SH; Youn YJ; Choi JW; Kim JK; Lee KS; Chon CY; Han KH
Oncology; 2007; 72 Suppl 1():52-7. PubMed ID: 18087182
[TBL] [Abstract][Full Text] [Related]
14. The combination of PIVKA-II and AFP improves the detection accuracy for HCC in HBV caucasian cirrhotics on long-term oral therapy.
Loglio A; Iavarone M; Facchetti F; Di Paolo D; Perbellini R; Lunghi G; Ceriotti F; Galli C; Sandri MT; Viganò M; Sangiovanni A; Colombo M; Lampertico P
Liver Int; 2020 Aug; 40(8):1987-1996. PubMed ID: 32301212
[TBL] [Abstract][Full Text] [Related]
15. Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II.
Caviglia GP; Abate ML; Gaia S; Petrini E; Bosco C; Olivero A; Rosso C; Ciancio A; Pellicano R; Saracco GM; Rizzetto M; Smedile A
Panminerva Med; 2017 Dec; 59(4):283-289. PubMed ID: 28650134
[TBL] [Abstract][Full Text] [Related]
16. Expression of estrogen-related gene markers in breast cancer tissue predicts aromatase inhibitor responsiveness.
Moy I; Lin Z; Rademaker AW; Reierstad S; Khan SA; Bulun SE
PLoS One; 2013; 8(11):e77543. PubMed ID: 24223121
[TBL] [Abstract][Full Text] [Related]
17. Clinical proteomics in cancer: Where we are.
Panis C; Pizzatti L; Souza GF; Abdelhay E
Cancer Lett; 2016 Nov; 382(2):231-239. PubMed ID: 27561426
[TBL] [Abstract][Full Text] [Related]
18. Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma. Comparison with alpha-fetoprotein.
Suehiro T; Sugimachi K; Matsumata T; Itasaka H; Taketomi A; Maeda T
Cancer; 1994 May; 73(10):2464-71. PubMed ID: 7513601
[TBL] [Abstract][Full Text] [Related]
19. High mobility group A protein-2 as a tumor cancer diagnostic and prognostic marker: a systematic review and meta-analysis.
Thi-Hai Pham Y; Utuama O; Thomas CE; Park JA; La Vecchia C; Risch HA; Tran CT; Le TV; Boffetta P; Raskin L; Luu HN
Eur J Cancer Prev; 2020 Nov; 29(6):565-581. PubMed ID: 32898013
[TBL] [Abstract][Full Text] [Related]
20. Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion.
Poté N; Cauchy F; Albuquerque M; Voitot H; Belghiti J; Castera L; Puy H; Bedossa P; Paradis V
J Hepatol; 2015 Apr; 62(4):848-54. PubMed ID: 25450201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]